SIGHT
GENSIGHT BIOLOGICS
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Gensight Biologics is a biotechnology company specializing in the development of gene therapies for neurodegenerative eye diseases.
GENSIGHT BIOLOGICS
SIGHT
Gensight Biologics is a biotechnology company specializing in the development of gene therapies for neurodegenerative eye diseases.
Price history of GENSIGHT BIOLOGICS
Price history of GENSIGHT BIOLOGICS
Performance & Momentum
GenSight Biologics Strengthens Funding and Regulatory Status
GenSight Biologics recently raised nearly €2.9 million, boosting its financial capacity to advance its innovative gene therapies. Additionally, the company secured key regulatory approvals: early access to the GS010/LUMEVOQ® treatment in Israel, compassionate use authorization in France, and approval for the REVISE dose-response study. These developments enhance commercialization prospects and increase the value of its pipeline, positively impacting the stock price.
Similar stocks to GENSIGHT BIOLOGICS
Recent News
GENSIGHT BIOLOGICS
GenSight Biologics Raises Nearly €5.7M in Funding
4 months agoGenSight Biologics, specializing in gene therapies for neurodegenerative diseases, announced two consecutive fundraising rounds totaling nearly €5.7 million in October and November 2025. At the same time, the company secured regulatory approvals for expanded access to its GS010/LUMEVOQ® treatment in the United States, strengthening its commercial outlook. These financial moves enhance cash visibility and support the development capacity of its innovative products, likely boosting its stock valuation.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
